Knockdown of GBP5 alleviates lipid accumulation and inflammation in alcoholic fatty liver through inhibition of NF-κB pathway in mice

Alcoholic liver disease (ALD) is a global liver disease that manifests in a variety of forms, including alcoholic hepatitis, liver inflammation, fatty liver, and liver cirrhosis. One of the early stages of ALD is alcoholic fatty liver (AFL) disease, which is primarily characterized by the accumulation of lipids and inflammation in hepatocytes. Guanylate binding protein 5 (GBP5) has been investigated for its involvement in disease progression. The regulatory effects of GBP5 on the progression of AFL disease are still not well understood. This study aims to investigate the impact of GBP5 on AFL progression and its underlying mechanism of action. To achieve this, gene expression was evaluated using western blot and reverse transcription quantitative polymerase chain reaction (RT-qPCR) methods. Lipid accumulation was confirmed using the Oil Red O staining assay, while the levels of Triglyceride (TG), aspartate aminotransferases (AST), and alanine aminotransferases (ALT) were measured using commercial kits. The levels of inflammatory cytokines were assessed using enzyme-linked immuno sorbent assay (ELISA) assay. Finally, cell apoptosis was evaluated using flow cytometry. Cell apoptosis was evaluated through flow cytometry. Our work demonstrated that GBP5 expression was up-regulated in the Ethyl Alcohol (EtOH) group. Additionally, lipid accumulation was increased after EtOH inducement, but this change was attenuated by silencing GBP5. Silencing of GBP5 reduced EtOH-mediated inflammation and cell apoptosis. Finally, it was discovered that knockdown of GBP5 retarded the EtOH-stimulated nuclear factor kappa-B (NF-κB) pathway. Knockdown of GBP5 alleviated lipid accumulation and inflammation in AFL through inhibition of NF-κB pathway. This finding suggested that GBP5 may be a useful bio-target for AFL treatment.

GBP5; Alcoholic fatty liver; Lipid accumulation; Inflammation; NF-κB pathway

[1] Singh H, Masih B, Satpathy SK, Duseja A, Chawla Y. Financial burden of alcohol abuse in patients with alcoholic liver disease. Tropical Gastroenterology. 2001; 22: 172.

[2] Kang SJ, Park ST, Ha GC, Ko KJ. Association between cardiorespiratory fitness, muscle strength, and non-alcoholic fatty liver disease in middle-aged men. Journal of Men’s Health. 2022; 18: 1–8.

[3] Dunn W, Shah VH. Pathogenesis of alcoholic liver disease. Clinical Liver Disease. 2016; 20: 445–456.

[4] Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol. 2004; 34: 9–19.

[5] Jiang Z, Gao J, Chai Y, Li W, Luo Y, Chen Y. Astragaloside alleviates alcoholic fatty liver disease by suppressing oxidative stress. The Kaohsiung Journal of Medical Sciences. 2021; 37: 718–729.

[6] Shenoy AR, Wellington DA, Kumar P, Kassa H, Booth CJ, Cresswell P, et al. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science. 2012; 336: 481–485.

[7] Li Y, Lin X, Wang W, Wang W, Cheng S, Huang Y, et al. The proinflammatory role of guanylate-binding protein 5 in inflammatory bowel diseases. Frontiers in Microbiology. 2022; 13: 926915.

[8] Liu N, Gao Y, Liu Y, Liu D. GBP5 inhibition ameliorates the progression of lupus nephritis by suppressing NLRP3 inflammasome activation. Immunological Investigations. 2023; 52: 52–66.

[9] Zhou L, Zhao H, Zhao H, Meng X, Zhao Z, Xie H, et al. GBP5 exacerbates rosacea-like skin inflammation by skewing macrophage polarization towards M1 phenotype through the NF-κB signalling pathway. Journal of the European Academy of Dermatology and Venereology. 2023; 37: 796–809.

[10] Guo H, Ni M, Xu J, Chen F, Yao Z, Yao Y, et al. Transcriptional enhancement of GBP-5 by BATF aggravates sepsis-associated liver injury via NLRP3 inflammasome activation. The FASEB Journal. 2021; 35: e21672.

[11] Ding K, Li X, Ren X, Ding N, Tao L, Dong X, et al. GBP5 promotes liver injury and inflammation by inducing hepatocyte apoptosis. The FASEB Journal. 2022; 36: e22119.

[12] Li Y, Wei M, Yuan Q, Liu Y, Tian T, Hou L, et al. MyD88 in hepatic stellate cells promotes the development of alcoholic fatty liver via the AKT pathway. Journal of Molecular Medicine. 2022; 100: 1071–1085.

[13] Wang W, Zhong G, Long K, Liu Y, Liu Y, Xu A. Silencing miR-181b-5p upregulates PIAS1 to repress oxidative stress and inflammatory response in rats with alcoholic fatty liver disease through inhibiting PRMT1. International Immunopharmacology. 2021; 101: 108151.

[14] Sun Y, Wu D, Yin N, Yang L, Chen X, Li H, et al. Arrb2 causes hepatic lipid metabolism disorder via AMPK pathway based on metabolomics in alcoholic fatty liver. Clinical Science. 2021; 135: 1213–1232.

[15] Jiang W, Wang J, Xue W, Xin J, Shi C, Wen J, et al. Caveolin-1 attenuates acetaminophen aggravated lipid accumulation in alcoholic fatty liver by activating mitophagy via the Pink-1/Parkin pathway. European Journal of Pharmacology. 2021; 908: 174324.

[16] You Y, Liu C, Liu T, Tian M, Wu N, Yu Z, et al. FNDC3B protects steatosis and ferroptosis via the AMPK pathway in alcoholic fatty liver disease. Free Radical Biology and Medicine. 2022; 193: 808–819.

[17] Cheng XY, Liu JD, Lu XY, Yan X, Huang C, Meng XM, et al. miR-203 inhibits alcohol-induced hepatic steatosis by targeting lipin1. Frontiers in Pharmacology. 2018; 9: 275.

[18] Lawrence T. The nuclear factor NF-κB pathway in inflammation. Cold Spring Harbor Perspectives in Biology. 2009; 1: a001651.

[19] Chen. F, Wang. W, Cai. X, Yu. H, Qu. C, Zhang. X, et al. Methyl jasmonate reduces the inflammation and apoptosis of HK-2 cells induced by LPS by regulating the NF-κB pathway. Signa Vitae. 2021; 17: 218–224.

[20] Zhang T, Hu J, Wang X, Zhao X, Li Z, Niu J, et al. MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-κB-TNFα pathway. Journal of Hepatology. 2019; 70: 87–96.

[21] Wu J, Yang G, Qi C, Zhou L, Hu J, Wang M. Anti-inflammatoryactivity of platycodin d on alcohol-induced fatty liver rats via TLR4-MYD88-NF-κB signal path. Africa Journal of Traditional Complementary and Alternative Medicine. 2016; 13: 176–183.

[22] Kong L, Chen J, Ji X, Qin Q, Yang H, Liu D, et al. Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPARα to activate the NF-κB signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance. Journal of Experimental & Clinical Cancer Research. 2021; 40: 18.